Navigation Links
Onconova Therapeutics Announces Presentation of Clinical and,Non-Clinical Results for Its Lead Compound ON 01910.Na at American,Association of Cancer Research Conference in Los Angeles

s, and the combination therapy was as well tolerated as Oxaliplatin treatment alone. This study supports further evaluation of ON 01910.Na and the combination with Oxaliplatin in additional clinical trials in patients with liver, hormone refractory prostate and melanoma tumors (abstract 2271).

An oral presentation, "Phase I study of ON 01910.Na, A Novel Cell Cycle Inhibitor in Adult Patients with Solid Tumors by A. Jimeno, J. Li, M.V.R Reddy, E.P Reddy, A. Chan, X. Zhang, P. Kulesza, J. Wheelhouse, G. Cusatis, A. Howard, M. Maniar, W.A Messersmith, D. Laheru, M. Rudek, S. D. Baker, M. Hidalgo, and R. C. Donehower, summarizes the Phase I study conducted at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Center, Baltimore, MD, in which ON 01910.Na has shown preliminary signs of clinical activity early in development. ON 01910.Na has also evidenced significant preclinical activity against a novel direct pancreatic cancer xenograft model. A gene expression-based assay identifies tumors likely to respond to ON 01910.Na, and will be tested in a Phase II clinical study in pancreatic cancer patients. Integrating early clinical and preclinical development programs is an efficient way to generate rationale for disease-directed studies and biomarkers (oral presentation in a "Breakthroughs in Clinical Research" session on Monday).

Additional scientific studies employing Onconova Therapeutics, Inc., anticancer compounds being presented at this meeting include: "Mass Spectrometric Study of Antibody Drug conjugates" by J. Roboz, S.Y. Cho, S. C. Bell, Glenn J. Fegley, J. L. Duke, S. C. Cosenza and J. F. Holland (abstract 920); "Mass Spectrometric Study of Drug Bound to Protein" by S.Y. Cho, J. Roboz, T. Ohnuma and J. F. Holland (abstract 3182); and "Evaluation of ON 01910.Na, a novel modulator of PLK-1 pathway and development of a cyclin B1 based predictive assay in pancreatic cancer" by A. Jimeno, A. Chan, G. Cusatis, X. Zhang, J. Wheelhouse, A
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... of the ResMed Data Exchange program, a comprehensive ... medical equipment (HME) and other health care providers. ... secure access to critical patient information. It integrates ... AirView™ and U-Sleep™ patient management platforms with customers, ...
(Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
(Date:10/20/2014)... 20, 2014 Pharmaceutic Labs announces the opening ... Albany, NY for admixing, compounding, drug ... and/or exceeds the FDA standards for safety and quality, ... 211. The 10,000 square foot outsourcing ... quality assurance and quality control. The company will produce ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... N.J., Jan. 6, 2012 Savient Pharmaceuticals, Inc. (NASDAQ: ... code, or permanent J-code, for KRYSTEXXA® (pegloticase) became available ... assigned by the Centers for Medicare and Medicaid Services ... process for prescribers of KRYSTEXXA, the first and only ...
... 6, 2012 Biodel Inc. (Nasdaq: BIOD ) ... of Biodel, will present a corporate update at the 30th ... 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). ... 2012, at the Westin St. Francis Hotel in San Francisco, ...
Cached Medicine Technology:Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 2Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 3Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 4Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 5Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA® 6
(Date:10/20/2014)... T.E.N., a technology and information security ... William H. Murray, renowned author and industry visionary, ... Award winner. Presented annually, the ISE® Luminary Leadership ... and industry practitioner for his or her distinguished ... security industry. , Formerly with IBM, Murray is ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned company ... absorbent products. The company has recently made efforts ... Tranquility® Premium Protection absorbent products. The company has ... packaging a new look, and is currently working on ... public. , The new website, developed with Thread Marketing ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... 2014 Punzoné , the first line ... has a lot to celebrate this month. October marks Italian ... achievements and contributions of Americans of Italian heritage and Italians ... today it shares its favorite Italian cocktails and encourages everyone ... - even if it is only in a glass. ...
(Date:10/19/2014)... BambooIndustry.com, one of the most popular suppliers of bamboo ... deckings . Moreover, the company has launched a special ... at deeply discounted rates. , As is known ... significance of online business nowadays. Thus, BambooIndustry.com pays a ... are striving to deliver both value and efficiency for ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2
... 2008) The Virginia Commonwealth University School of Medicine ... from the National Institutes of Healths National Institute on ... syndrome, a disorder of the endocrine system that affects ... syndrome, or PCOS, causes hormonal imbalances leading to irregular ...
... LAKE CITY, May 12 Dynatronics,Corporation (Nasdaq: ... quarter,ended March 31, 2008 on Wednesday, May 14, ... for investors later that,day at 2:30 p.m. ET ... nine month,periods. Those interested in participating should call ...
... to expand oral health care services; awards two significant oral health ... ... As part of the Illinois,Children,s Healthcare Foundation,s (ILCHF) $20 million, five-year,initiative to ... to announce a request for proposals in the oral,health care field. The ...
... http://www.cryocath.com Toronto Stock Exchange Symbol: CYT, MONTREAL, ... in cryotherapy products to treat cardiac,arrhythmias, today announced financial ... Selected Second Quarter Financial and Operational Highlights:, ... to $10.2 million or a 37.6% ...
... MELVILLE, N.Y., May 12 Gentiva Health,Services, Inc. (Nasdaq: ... health services, announced today that it is scheduled to,present ... 21, 2008 at the 2008,Citi Investment Research Global Health ... be available to the public via a live audio ...
... Low IQ more likely the younger a child is at diagnosis, ... about 5 percent of people with multiple sclerosis are diagnosed when ... cognitive function, causing memory and attention problems, and possibly low IQ ... time of diagnosis, the more likely he or she is to ...
Cached Medicine News:Health News:NIH grant to support Translational Research Center for PCOS 2Health News:Children in Illinois to Have Healthier Smiles 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 3Health News:Multiple Sclerosis Affects Children's Cognitive Skills 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 3
Schlesinger Laminectomie Rongeur, golden springs. 15 cm - 6, with narrow footplate, large handle, 40 down-cutting, jaws 3 mm wide....
... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
Codman Hakim Programmable micro with Rickham Reservoir offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often ch...
... Osteopal V is a low viscosity ... use in vertebroplasty. The bone cement is ... stabilization purposes. Osteopal V is used for ... concentration of zirconium dioxide is included in ...
Medicine Products: